Does the risk of death from breast cancer after tamoxifen treatment increase when selective serotonin reuptake inhibitor antidepressants have been co-prescribed?
- Kelly, C.M., Juurlink, D.N., Gomes, T., Duong-Hua, M., Pritchard, K.I., Austin, P.C., Paszat, L.F., 2010. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. BMJ 340, c693–c693.
- 2,430 women
A population based study among female residents of Ontario, Canada, who were aged 66 years or older and who started tamoxifen treatment between 1 January 1993 and 31 December 2005
- Of 2,430 women treated with tamoxifen and a single SSRI, 374 died of breast cancer during follow up.
- Use of paroxetine during tamoxifen treatment is associated with an increased subsequent risk of death due to breast cancer in a fashion that correlates with the duration of combined use. By contrast, no such risk was seen with other antidepressants.
- Yes (with confidence)
Breast cancer is the most commonly diagnosed cancer in women worldwide, and it is estimated that 1.5 million new cases will be diagnosed in 2010